Anti-EGFR Antibody

EGFR antibody

Boster Bio Anti-EGFR Antibody (Catalog # A00023-1). Tested in IHC, IP, WB applications. This antibody reacts with Human, Rat.

Product Info Summary

SKU: A00023-1
Size: 250uL
Reactive Species: Human, Rat
Host: Rabbit
Application: ELISA, IP, IHC, WB

Customers Who Bought This Also Bought

Product Name

Anti-EGFR Antibody

View all EGFR Antibodies

SKU/Catalog Number

A00023-1

Size

250uL

Form

Liquid (sterile filtered)

Description

Boster Bio Anti-EGFR Antibody (Catalog # A00023-1). Tested in IHC, IP, WB applications. This antibody reacts with Human, Rat.

Storage & Handling

Store vial at -20°C prior to opening. Aliquot contents and freeze at -20°C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4°C as an undiluted liquid. Dilute only prior to immediate use. Expiration date is one (1) year from date of opening. (Ship on dry ice.)

Cite This Product

Anti-EGFR Antibody (Boster Biological Technology, Pleasanton CA, USA, Catalog # A00023-1)

Host

Rabbit

Contents

0.01% (w/v) Sodium Azide

Clonality

Polyclonal

Isotype

Antiserum

Immunogen

This whole rabbit serum was prepared by repeated immunizations with a peptide synthesized using conventional technology.  The sequence of the epitope maps to a region near the carboxy terminus which is identical in human, mouse and rat EGFR.

Reactive Species

A00023-1 is reactive to EGFR in Human, Rat

Observed Molecular Weight

68 kDa

Calculated molecular weight

134.3 kDa

Background of EGFR

EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial to maintaining a normal balance in cell growth and development. Growth factor receptors are involved not only in promoting the proliferation of normal cells but also in the aberrant growth of many types of human tumors. For example, the epidermal growth factor receptor (EGFR) is mutated and/or over-expressed in many common solid human squamous cell carcinomas including breast, brain, bladder, lung, gastric, head & neck, esophagus, cervix, vulva, ovary, and endometrium. Over-expression of the EGFR gene occurs in carcinomas with and without gene amplification. EGFR and ErbB-2 are particularly important in breast cancer because increased production or activation has been associated with poor prognosis. EGFR belongs to a family of growth factor receptors, which also includes ErbB-2/HER-2/neu, ErbB-3/HER-3/neu and ErbB-4/HER-4/neu. EGFR can heterodimerize with each of the members of this family.

Antibody Validation

Boster validates all antibodies on WB, IHC, ICC, Immunofluorescence, and ELISA with known positive control and negative samples to ensure specificity and high affinity, including thorough antibody incubations.

View more details

Applications

A00023-1 is guaranteed for ELISA, IP, IHC, WB Boster Guarantee

Assay Dilutions Recommendation

The recommendations below provide a starting point for assay optimization. The actual working concentration varies and should be decided by the user.

ELISA: 1:10,000 - 1:50,000
IHC: 2.5 µg/mL
IP: 10 µl
WB: 1:1,000 - 1:10,000
Anti-EGFR antibody has been tested by and is specifically designed for ELISA, immunoblotting, immunoprecipitation, and immunohistochemistry.  Reactivity in other assays is likely, but has not been determined.  Recognition of EGFR is independent of the phosphorylation status at tyrosine 1173.   A431 cells, keratinocytes in normal epidermis, or placenta are typically used as positive control sources.  The antigen is typically localized in the cell membrane.   For western blotting, good results are also achieved on PVDF membranes blocked with 5% lowfat milk diluted in TTBS for 1 hour at room temperature.  Also, dilute the primary antibody and secondary in 5% lowfat milk in TTBS.   Anti-EGFR can be diluted up to 1:10,000 for immunoblot depending on the cell line and the amount of EGFR in a particular lysate.  For immunoprecipitation, use approximately 10 µl of the antibody.  The immunoprecipitation mix should contain the antibody, 25 µl of Protein A-agarose beads and 1.0 ml of lysate (lysate contains approximately 1.0 mg of total protein).  This mixture should be rotated overnight at 4°C and then washed 3 times with lysis buffer (used to prepare the lysate).  The resulting bead complex is dissolved in 20-30 µl of 3X SDS-PAGE sample buffer and approximately 15 µl is loaded per lane on an 8% polyacrylamide gel.

Validation Images & Assay Conditions

Loading publications

No publications found

Do you have publications using this product? Share with us and receive a reward. Contact us for more information.

Publications not available. Please try again later.

Product has been cited in publications

No results found matching your query

  • Published: --- Journal: --- Application: --- Impact Factor: --- Species: --- PMID: --- View Article

Have you used Anti-EGFR Antibody?

Share your experimental results or join a short interview to earn up to $1,000 in product credits or other rewards.

0 Reviews For Anti-EGFR Antibody

Have a question?

Find answers in Q&As, reviews.

Can't find your answer?

Submit your question

0 Customer Q&As for Anti-EGFR Antibody

Order DetailsPrice
A00023-1-A00023-1

250uL

$641

Free Secondary Antibody

FREE  $95.00
FREE  $95.00
$40.00  $80.00
$75.00  $150.00
$30.00  $60.00
$75.00  $150.00
$65.00  $130.00
$55.00  $110.00
$67.50  $135.00
Choose an option to show lead time.
Get A Quote
In stock
Order Product
A00023-1
Buy one primary antibody get one 0.5ml HRP or Biotin secondary antibody for free.
*Sample sizes are prepared on demand and will take extra lead time. (cannot be conjugated)
$641.00

Troubleshooting

troubleshooting-box-image

Download troubleshooting handbooks for IHC, Western blot and ELISA for FREE.

Download Free PDFs Now

Boster Guarantee

Guaranteed product quality

Guaranteed product quality

We promise all of our products perform as described in datasheets.

This product is for Research Use Only. Not for use in diagnostic procedures.

Update date: Apr 11, 2026